Sarcoma

120 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.

Broader: Neoplasms

Narrower: Carcinosarcoma 4, Dermatofibrosarcoma 5, Desmoplastic Small Round Cell Tumor 1, Hemangiosarcoma 7, Histiocytoma, Malignant Fibrous 6, Leiomyosarcoma 11, Liposarcoma 10, Liposarcoma, Myxoid 5, Osteosarcoma 18, Rhabdomyosarcoma 14, Rhabdomyosarcoma, Alveolar 3, Rhabdomyosarcoma, Embryonal 3, Sarcoma, Clear Cell 3, Sarcoma, Ewing 7, Sarcoma, Synovial 9

Treatments and conditions

Sarcoma
Treatment and conditionWhere it standsTrials
Abemaciclib + Irinotecan + Temozolomide for sarcoma, ewingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Archive Sample Retrieval + Biospecimen Collection + pH Low Insertion Peptide-exatecan Conjugate CBX-12 + Radiologic Imaging Procedure for rhabdomyosarcomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Archive Sample Retrieval + Biospecimen Collection + pH Low Insertion Peptide-exatecan Conjugate CBX-12 + Radiologic Imaging Procedure for sarcoma, ewingTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Atezolizumab for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ATEZOLIZUMAB + Doxorubicin hydrochloride for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ATEZOLIZUMAB + Vincristine + Irinotecan + Temozolomide for rhabdomyosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy for osteosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biospecimen Collection + Diagnostic Imaging Testing + Excisional Biopsy + Minimally Invasive Surgery + Pelvic Lymphadenectomy + Questionnaire Administration + Sentinel Lymph Node Mapping + Indocyanine Green for carcinosarcomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Brachytherapy for osteosarcomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + ELRAGLUSIB for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + ELRAGLUSIB + Paclitaxel for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS) for sarcoma, ewingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cyclophosphamide + VINORELBINE for rhabdomyosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dacarbazine for leiomyosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Definitive radiotherapy for dermatofibrosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Definitive radiotherapy for histiocytoma, malignant fibrousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Definitive radiotherapy for leiomyosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Definitive radiotherapy for liposarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Definitive radiotherapy for sarcoma, synovialPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
DOCETAXEL + Hydroxychloroquine + Gemcitabine for osteosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Doxorubicin hydrochloride + ELRAGLUSIB for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Durvalumab + oleclumab for hemangiosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Durvalumab + oleclumab for liposarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Durvalumab + oleclumab for osteosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Echocardiography + Biospecimen Collection + Computed Tomography + Multigated Acquisition Scan + Zanzalintinib for leiomyosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Echocardiography + Biospecimen Collection + Computed Tomography + Multigated Acquisition Scan + Zanzalintinib for sarcoma, ewingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Echocardiography + Biospecimen Collection + Computed Tomography + Multigated Acquisition Scan + Zanzalintinib for sarcoma, synovialPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Elraglusib for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ELRAGLUSIB + Gemcitabine Hydrochloride for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ELRAGLUSIB + NAB-PACLITAXEL + Gemcitabine Hydrochloride for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Filgrastim, peg-filgrastim + Liposomal irinotecan + Proton beam radiation or external beam radiation or brachytherapy + Surgical Resection + DACTINOMYCIN + Vincristine + Cyclophosphamide + VINORELBINE for rhabdomyosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Filgrastim, peg-filgrastim + Liposomal irinotecan + Proton beam radiation or external beam radiation or brachytherapy + Surgical Resection + DACTINOMYCIN + Vincristine + Cyclophosphamide + VINORELBINE + Temozolomide for rhabdomyosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
GI-102 for sarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GI-102 + BEVACIZUMAB + Paclitaxel for sarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GI-102 + Doxorubicin for sarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GI-102 + Eribulin for sarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GI-102 + PEMBROLIZUMAB for sarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GI-102 + TRASTUZUMAB DERUXTECAN for sarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GI-102 subcutaneous (SC) for sarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
HS-20093 for osteosarcomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Intensity-modulated radiation therapy (IMRT) for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Irinotecan + ELRAGLUSIB for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Irinotecan + Temozolomide for sarcoma, ewingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Irinotecan Hydrochloride Liposome Injection(II) combined with temozolomide and bevacizuma for sarcomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Iscador*P for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ivonescimab for leiomyosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + DACTINOMYCIN + Cyclophosphamide + Vincristine Sulfate for rhabdomyosarcoma, alveolarPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + DACTINOMYCIN + Cyclophosphamide + Vincristine Sulfate for rhabdomyosarcoma, embryonalPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + IRINOTECAN HYDROCHLORIDE + DACTINOMYCIN + Cyclophosphamide + Vincristine Sulfate for rhabdomyosarcoma, alveolarPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + IRINOTECAN HYDROCHLORIDE + DACTINOMYCIN + Cyclophosphamide + Vincristine Sulfate for rhabdomyosarcoma, embryonalPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + IRINOTECAN HYDROCHLORIDE + DACTINOMYCIN + TEMSIROLIMUS + Cyclophosphamide + VINORELBINE + Vincristine Sulfate for rhabdomyosarcoma, alveolarPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + IRINOTECAN HYDROCHLORIDE + DACTINOMYCIN + TEMSIROLIMUS + Cyclophosphamide + VINORELBINE + Vincristine Sulfate for rhabdomyosarcoma, embryonalPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Letetresgene autoleucel (lete-cel, GSK3377794) + Cyclophosphamide + FLUDARABINE for liposarcoma, myxoidPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Letetresgene autoleucel (lete-cel, GSK3377794) + Cyclophosphamide + FLUDARABINE for sarcoma, synovialPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lifileucel for histiocytoma, malignant fibrousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lifileucel for liposarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lomustine + ELRAGLUSIB for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lurbinectedin for leiomyosarcomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for carcinosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for hemangiosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for carcinosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for hemangiosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Naxitamab for sarcoma, ewingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Neoadjuvant Radiation + Surgery + TALIMOGENE LAHERPAREPVEC for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nivolumab for sarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
NIVOLUMAB + Catequentinib for sarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nivolumab + ipilimumab + trabectedin for sarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Onfekafusp alfa for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Paclitaxel Polymer Micelles + Gemcitabine + Anlotinib for sarcomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Paclitaxel Polymer Micelles + Gemcitabine + Lenvatinib for sarcomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Pembrolizumab for carcinosarcomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Peptide vaccine IPX for rhabdomyosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Peptide vaccine IPX for sarcoma, ewingPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Peptide vaccine IPX for sarcoma, synovialPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation or external beam radiation or brachytherapy + Surgical Resection + DACTINOMYCIN + Vincristine + Cyclophosphamide for rhabdomyosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection for dermatofibrosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection for hemangiosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection for histiocytoma, malignant fibrousPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection for leiomyosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection for liposarcoma, myxoidPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection for osteosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection for sarcoma, clear cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection for sarcoma, synovialPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for dermatofibrosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for hemangiosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for histiocytoma, malignant fibrousPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for leiomyosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for liposarcoma, myxoidPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for osteosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for sarcoma, clear cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for sarcoma, synovialPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for dermatofibrosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for hemangiosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for histiocytoma, malignant fibrousPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for leiomyosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for liposarcoma, myxoidPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for osteosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for sarcoma, clear cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for sarcoma, synovialPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Quality of Life + Functional outcome + preoperative for dermatofibrosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Quality of Life + Functional outcome + preoperative for histiocytoma, malignant fibrousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Quality of Life + Functional outcome + preoperative for leiomyosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Quality of Life + Functional outcome + preoperative for liposarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Quality of Life + Functional outcome + preoperative for sarcoma, synovialPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Radiation Therapy for sarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Radiotherapy + TRABECTEDIN for leiomyosarcomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Radiotherapy + TRABECTEDIN for liposarcoma, myxoidTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Regorafenib for osteosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Siremadlin + PAZOPANIB for sarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Spartalizumab for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Talimogene laherparepvec + nivolumab + trabectedin for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tislelizumab for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tislelizumab+liposomal doxorubicin+ifosfamide for desmoplastic small round cell tumorPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tislelizumab+liposomal doxorubicin+ifosfamide for hemangiosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tislelizumab+liposomal doxorubicin+ifosfamide for leiomyosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tislelizumab+liposomal doxorubicin+ifosfamide for liposarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Trametinib + Doxorubicin + CISPLATIN + Gefitinib + Disulfiram + SUNITINIB + Methotrexate for osteosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Trametinib + Gefitinib + Disulfiram + Ifosfamide + SUNITINIB for osteosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Vinorelbine for rhabdomyosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ZI-MA4-1 (TCR-NK cells) + Cyclophosphamide + FLUDARABINE for sarcoma, synovialPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1

Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.